Literature DB >> 10670588

AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun.

B L Faubert1, N E Kaminski.   

Abstract

Regulation of the activator protein-1 (AP-1) complex is very intricate because it involves phosphorylation state, protein-protein, and protein-DNA interactions. In these studies, the regulation of AP-1 activity, with emphasis on c-fos and c-jun regulation, was investigated using cannabinol (CBN) in primary mouse splenocytes in vitro. Cannabinoid compounds exhibit immunosuppressive actions that are putatively mediated through Gi-protein coupled receptors that negatively regulate adenylate cyclase. However, recent studies suggest that cannabinoids modulate other signaling cascades. Indeed, we demonstrate that CBN inhibited binding to AP-1-containing sites from the interleukin-2 promoter. This inhibition of binding was, in part, due to decreased nuclear expression of c-fos and c-jun. We further determined that the effects of CBN were due to posttranslational modifications of these phosphoproteins and showed that CBN inhibited the activation of ERK MAP kinases. Thus, cannabinoid-induced immunosuppression involves disruption of the ERK signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10670588     DOI: 10.1002/jlb.67.2.259

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  12 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-30       Impact factor: 4.219

Review 3.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

4.  Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120.

Authors:  Weimin Chen; Barbara L F Kaplan; Schuyler T Pike; Lauren A Topper; Nicholas R Lichorobiec; Steven O Simmons; Ram Ramabhadran; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2012-08-16       Impact factor: 4.962

5.  Involvement of Blimp-1 and AP-1 dysregulation in the 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated suppression of the IgM response by B cells.

Authors:  Dina Schneider; Maria A Manzan; Byung Sun Yoo; Robert B Crawford; Norbert Kaminski
Journal:  Toxicol Sci       Date:  2009-02-23       Impact factor: 4.849

6.  Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway.

Authors:  Chun-Hui Wang; Cheng-Wei Tang; Chun-Lun Liu; Li-Ping Tang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

7.  Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.

Authors:  Haitian Lu; Barbara L F Kaplan; Thitirat Ngaotepprutaram; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

8.  Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor.

Authors:  B Bosier; E Hermans; Dm Lambert
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

9.  The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT).

Authors:  Barbara L F Kaplan; Alison E B Springs; Norbert E Kaminski
Journal:  Biochem Pharmacol       Date:  2008-07-08       Impact factor: 5.858

10.  Constitutive stimulatory G protein activity in limb mesenchyme impairs bone growth.

Authors:  Anara Karaca; Vijayram Reddy Malladi; Yan Zhu; Olta Tafaj; Elena Paltrinieri; Joy Y Wu; Qing He; Murat Bastepe
Journal:  Bone       Date:  2018-02-20       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.